Knee OA: Naproxcinod performs comparably to naproxen .
Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study
Semin Arthritis Rheum. 2011 Feb;40(4):285-971020 patients with knee osteoarthritis were randomized in order to evaluate the efficacy and safety of naproxcinod treatments compared with placebo and conventional nonsteroidal anti-inflammatory drugs (naproxen 500mg). The study primarily assessed patients for efficacy using the WOMAC pain and function subscales along with several long-term secondary measures (including blood pressure,safety and adverse events). The study concluded that naproxcinod at both tested doses of 350mg and 750mg was superior to placebo controls and performed comparably to the naproxen 500mg over a full year of treatment.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
